Skip to content

Cleo Delivers Early Progress on Development Program

By API User

Highlights Selection of biomarkers panel for Cleo’s ovarian cancer test-kit has been finalised Antibody development has advanced increasing confidence for commercial assay development and upscaling for commercial manufacturing The Company is in final stages evaluating four commercial antibody manufacturing partners MELBOURNE, AUSTRALIA, 9 October, 2023: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or … Continued

ZeptoMetrix Awarded in Vitro Diagnostic Regulation (IVDR) Certification

By API User

BUFFALO, NY / ACCESSWIRE / October 3, 2023 / ZeptoMetrix® is pleased to announce it has been awarded an IVDR Quality Management System certificate from British Standards Institution BSI, NB 2797, one of the notified bodies under the new EU In Vitro Diagnostics Regulation (IVDR). This certificate applies to the majority of the current portfolio … Continued

HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101

By API User

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today announced that the first patient … Continued

Hyris Supports Researchers and Developers to Launch Testing Kits via New Onboarding Programs

By API User

Following the launch of its Marketplace in 2022, Hyris continues to leverage the AI capabilities of its genetic testing platform, renowned for its adaptability, to support both researchers and kit developers worldwide. New onboarding programs enable emerging players to accelerate their go-to-market, as well as established manufacturers and diagnostic providers to integrate their portfolio with … Continued

Meet Australia’s First Carbon-Neutral Pet Crematorium that Revolutionizes Aftercare with Renewable Energy and Special Tributes

By API User

BRISBANE, AU – 26-Sep-2023 Pure Souls Pet Aquacremation, Australia’s first carbon-neutral pet crematorium, is excited to announce its array of high-quality, environmentally-conscious services. Recognized as the top-rated pet aquacremation facility on Google, Pure Souls leverages the power of renewable energy to provide pet owners a sustainable, kind alternative to traditional pet cremation.   Operating exclusively on … Continued

INOVIQ and ResearchDx sign USA EXO-NET Services Agreement

By API User

Melbourne, Australia and Irvine, CA USA, 5 September 2023 (AEST): INOVIQ Limited (ASX:IIQ) (INOVIQ), a developer of next-generation exosome solutions and precision diagnostics, and ResearchDx Inc (ResearchDx), a Contract Diagnostics Organization (CDO) offering complete in vitro diagnostic (IVD) services, today announced a license and supply agreement for INOVIQ’s EXO-NET® exosome capture technology to enable provision of exosome isolation, biomarker discovery and diagnostics development services in the USA. The ResearchDx partnership builds on the previously announced Joint Marketing Agreement for INOVIQ’s EXO-NET exosome capture technology and Promega Nucleic Acid purification systems (ASX: 6 July2023). EXO-NET license agreement to ResearchDx INOVIQ and ResearchDx have signed a license and supply agreement that will enable the companies todeliver EXO-NET enabled High-Throughput (HT) exosome isolation, biomarker discovery and diagnostics development services to customers in the USA. Establishment of EXO-NET services in the USA follows the recent introduction of INOVIQ’s EXO-NET services from its Australian laboratory (see below). This new agreement combines the expertise … Continued

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

By API User

SHANGHAI, CHINA and TAIPEI, TAIWAN / ACCESSWIRE / August 28, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines, and Shanghai Henlius Biotech, Inc., a global biopharmaceutical company developing biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases, today announced that the two … Continued